Literature DB >> 25798273

Pretreatment tumor standardized uptake value as a prognostic factor in primary head and neck squamous cell carcinoma.

Baitao Zhang1, Fang Nie2, Bin Jin1, Qinghong Meng1, Pin Dong1.   

Abstract

Our objective was to conduct a systematic review and meta-analysis of studies assessing the diagnostic performance of primary tumor standardized uptake value (SUV) in head and neck squamous cell carcinoma (HNSCC), as measured by positron emission tomography. A systematic search of the indexed medical literature was conducted using appropriate keywords to identify relevant studies. Six articles were identified by searching electronic databases. A statistical analysis was performed with RevMan 4.2.2 software. SUV measurement and the SUV threshold for defining high SUV were studied dependently. For each publication, we first obtained an estimate of the relative risk (RR) for comparing patients with a low and those with a high SUV. Subsequently, we aggregated the individual RRs into a combined RR using the fixed-effects model to yield weighted mean pooled estimates with 95% confidence intervals (CIs). Publication bias was assessed with a funnel plot. A total of 6 clinical trials involving 453 patients were included in the meta-analysis. The combined RR from the 6 reports for local control was 0.72 (95% CI: 0.63-0.81). The funnel plot revealed symmetrical distribution, indicating no evidence of significant publication bias. The increase in the SUV of the primary tumor was found to be a poor prognostic marker for patients with HNSCC in the meta-analysis, which requires further confirmation in a meta-analysis based on individual patient data.

Entities:  

Keywords:  head and neck squamous cell carcinoma; local control; meta-analysis; positron emission tomography; primary tumor; standardized uptake value

Year:  2014        PMID: 25798273      PMCID: PMC4360643          DOI: 10.3892/mco.2014.464

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  17 in total

1.  Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group.

Authors:  J F Vansteenkiste; S G Stroobants; P J Dupont; P R De Leyn; E K Verbeken; G J Deneffe; L A Mortelmans; M G Demedts
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

2.  2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx.

Authors:  J-L Roh; K H Pae; S-H Choi; J S Kim; S Lee; S-B Kim; S Y Nam; S Y Kim
Journal:  Eur J Surg Oncol       Date:  2007-02-15       Impact factor: 4.424

3.  Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy.

Authors:  Abdelkarim S Allal; Pavel Dulguerov; Mohamed Allaoua; Charles-André Haenggeli; El Abbes El-Ghazi; Willy Lehmann; Daniel O Slosman
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

4.  FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma.

Authors:  Eva Brun; Elisabeth Kjellén; Jan Tennvall; Tomas Ohlsson; Anders Sandell; Roland Perfekt; Roland Perfekt; Johan Wennerberg; Sven Erik Strand
Journal:  Head Neck       Date:  2002-02       Impact factor: 3.147

5.  Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx.

Authors:  Sang Yoon Kim; Jong-Lyel Roh; Mi Ra Kim; Jae Seung Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang-wook Lee; Sung-Bae Kim
Journal:  J Nucl Med       Date:  2007-05       Impact factor: 10.057

Review 6.  Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project.

Authors:  Thierry Berghmans; Michèle Dusart; Marianne Paesmans; Claude Hossein-Foucher; Irene Buvat; Catherine Castaigne; Arnaud Scherpereel; Céline Mascaux; Michel Moreau; Martine Roelandts; Stéphane Alard; Anne-Pascale Meert; Edward F Patz; Jean-Jacques Lafitte; Jean-Paul Sculier
Journal:  J Thorac Oncol       Date:  2008-01       Impact factor: 15.609

7.  Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose.

Authors:  Abdelkarim S Allal; Daniel O Slosman; Tayeb Kebdani; Mohamed Allaoua; Willy Lehmann; Pavel Dulguerov
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-08-01       Impact factor: 7.038

8.  Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes.

Authors:  Chun-Ta Liao; Joseph Tung-Chieh Chang; Hung-Ming Wang; Shu-Hang Ng; Chuen Hsueh; Li-Yu Lee; Chih-Hung Lin; I-How Chen; Shiang-Fu Huang; Ann-Joy Cheng; Lai-Chu See; Tzu-Chen Yen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-02       Impact factor: 7.038

9.  Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer.

Authors:  Julie G Izzo; Vassiliki A Papadimitrakopoulou; Diane D Liu; Petra L C den Hollander; Ilona M Babenko; Jamie Keck; Adel K El-Naggar; Dong M Shin; J Jack Lee; Waun K Hong; Walter N Hittelman
Journal:  J Natl Cancer Inst       Date:  2003-02-05       Impact factor: 13.506

Review 10.  Clinical applications of PET in oncology.

Authors:  Eric M Rohren; Timothy G Turkington; R Edward Coleman
Journal:  Radiology       Date:  2004-03-24       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.